Stock Groups

EU regulator begins real-time review of Valneva’s COVID-19 shot -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO – The Valneva SE logo is seen at its headquarters in Saint-Herblain near Nantes France on September 13, 2021. REUTERS/Stephane Mahe

(Reuters) – On Thursday, the European Union’s drug regulator announced that it has begun a continuous review of Valneva’s protein-based COVID-19 vaccination. This comes weeks after the EU had signed a supply agreement with Valneva.

According to the European Medicines Agency, (EMA), the preliminary research suggests that VLA2001 triggers an antibody reaction against coronavirus. The European Medicines Agency (EMA), stated in a statement, “The decision to begin the real-time evaluation was based upon the findings of preliminary studies.”

The EMA is also reviewing COVID-19 vaccines, from Russia’s Gamaleya Institute, Sanofi -GSK, and Sinovac.

Last month, the European Commission signed eighth agreement with Valneva for the COVID-19 vaccine. The company will supply 60 million doses over the next two years.

Valneva claimed in October that the vaccine was “at least equally good, or better than AstraZeneca”‘s (NASDAQ) shot. The late-stage trials compared both, and showed significantly less side effects.

AstraZeneca’s vaccine has been approved by the EU. The same goes for shots from Pfizer BioNTech. Moderna (NASDAQ:) and Johnson & Johnson (NYSE:).

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses you may incur due to the use of these data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damage arising from the use of this information, including chart data, or buy/sell signal signals. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.

[ad_2]